1. Search Result
Search Result
Results for "

ATRA

" in MedChemExpress (MCE) Product Catalog:

18

Inhibitors & Agonists

2

Fluorescent Dye

2

Biochemical Assay Reagents

3

Natural
Products

4

Isotope-Labeled Compounds

1

GMP Molecules

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-14649
    Retinoic acid
    125+ Cited Publications

    Vitamin A acid; all-trans-Retinoic acid; ATRA

    Organoid RAR/RXR PPAR Endogenous Metabolite Autophagy Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Retinoic acid is a metabolite of vitamin A that plays important roles in cell growth, differentiation, and organogenesis. Retinoic acid is a natural agonist of RAR nuclear receptors, with IC50s of 14 nM for RARα/β/γ. Retinoic acid bind to PPARβ/δ with Kd of 17 nM. Retinoic acid acts as an inhibitor of transcription factor Nrf2 through activation of retinoic acid receptor alpha.
    Retinoic acid
  • HY-14649R
    Retinoic acid (Standard)
    125+ Cited Publications

    Vitamin A acid (Standard); all-trans-Retinoic acid (Standard); ATRA (Standard)

    Reference Standards RAR/RXR PPAR Endogenous Metabolite Autophagy Cancer
    Retinoic acid (Standard) is the analytical standard of Retinoic acid. This product is intended for research and analytical applications. Retinoic acid is a metabolite of vitamin A that plays important roles in cell growth, differentiation, and organogenesis. Retinoic acid is a natural agonist of RAR nuclear receptors, with IC50s of 14 nM for RARα/β/γ. Retinoic acid bind to PPARβ/δ with Kd of 17 nM. Retinoic acid acts as an inhibitor of transcription factor Nrf2 through activation of retinoic acid receptor alpha.
    Retinoic acid (Standard)
  • HY-14649G

    Vitamin A acid; all-trans-Retinoic acid; ATRA

    RAR/RXR PPAR Endogenous Metabolite Autophagy Cancer
    Retinoic acid (Vitamin A acid) (GMP) is Retinoic acid (HY-14649) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Retinoic acid is an agonist of RAR nuclear receptors .
    Retinoic acid
  • HY-12887

    RP 73401; RPR 73401

    Phosphodiesterase (PDE) Inflammation/Immunology Cancer
    Piclamilast (RP 73401) is a phosphodiesterase 4 (PDE4) inhibitor, with IC50 values of 16 nM and 2 nM in pig aorta and eosinophil soluble, respectively .
    Piclamilast
  • HY-NP004

    CVF

    Complement System Inflammation/Immunology
    Cobra Venom Factor (CVF) is a selective activator targeting complement components C3, C5, and factor B in the complement system. After binding to factor B, Cobra Venom Factor is cleaved by factor D, forming a stable C3/C5 convertase resistant to regulatory proteins H and I. This continuously hydrolyzes C3 and C5, depleting serum complement while inducing neutrophil migration, vascular leakage, and increased TNF-α levels. Cobra Venom Factor can be used to deplete complement and mimic complement activation-related pathological states, and is applied in animal models of complement-mediated diseases such as acute respiratory distress syndrome (ARDS), sepsis, and shock. Cobra Venom Factor can be isolated from the venom of cobras (e.g., Naja atra, Naja melanoleuca, Naja kaouthia, etc.) .
    Cobra Venom Factor
  • HY-141793

    Biotin-ATRA-conjugate

    RAR/RXR PPAR Endogenous Metabolite Autophagy Cancer
    ATRA-biotin (Biotin-ATRA-conjugate) is a biotin-conjugated ATRA. ATRA-biotin can be used to track ATRA in cells or a given tissue .
    ATRA-biotin
  • HY-14649S4

    Vitamin A acid-d5; all-trans-Retinoic acid-d5; ATRA-d5

    Isotope-Labeled Compounds RAR/RXR PPAR Endogenous Metabolite Autophagy Cancer
    Retinoic acid-d5 is the the deuterium labeled Retinoic acid (HY-14649). Retinoic acid is a metabolite of vitamin A that plays important roles in cell growth, differentiation, and organogenesis. Retinoic acid is a natural agonist of RAR nuclear receptors, with IC50s of 14 nM for RARα/β/γ. Retinoic acid bind to PPARβ/δ with Kd of 17 nM. Retinoic acid acts as an inhibitor of transcription factor Nrf2 through activation of retinoic acid receptor alpha .
    Retinoic acid-d5
  • HY-108531

    RAR/RXR Metabolic Disease
    ER 50891 is a RARα antagonist. ER 50891 can significantly antagonize the inhibitory effect of all-trans retinoic acid (ATRA) on the total cell metabolic activity and proliferation of MC3T3-E1 preosteoblasts. ER 50891 rescues ATRA-inhibited osteocalcin (OCN) expression and extracellular matrix mineralization, and suppresses alkaline phosphatase (ALP) activity synergistically. ER 50891 can be used for the study of osteoporosis related to ATRA-induced inhibition of osteoblastogenesis .
    ER 50891
  • HY-D1190

    RAR/RXR Others
    DC271 is a RAR agonist and synthetic retinoid that binds to the retinoid-binding site of cellular retinoic acid-binding protein II (CRBP-II). DC271 exhibits solvatochromic fluorescence properties: it produces intense blue-shifted emission in nonpolar environments and weak red-shifted emission in polar environments, and its severe fluorescence quenching in aqueous solutions can be reversed by embedding in the hydrophobic retinoid-binding protein pocket. DC271 enables direct detection of the binding between unlabeled compounds and related retinoid-binding proteins via fluorescence competition assays (Ex/Em = 355 nm/460 nm) .
    DC271
  • HY-108531A

    RAR/RXR Cancer
    ER 50891 quarterhydrate is a RARα antagonist. ER 50891 can significantly antagonize the inhibitory effect of all-trans retinoic acid (ATRA) on the total cell metabolic activity and proliferation of MC3T3-E1 preosteoblasts. ER 50891 rescues ATRA-inhibited osteocalcin (OCN) expression and extracellular matrix mineralization, and suppresses alkaline phosphatase (ALP) activity synergistically. ER 50891 can be used for the study of osteoporosis related to ATRA-induced inhibition of osteoblastogenesis .
    ER 50891 quarterhydrate
  • HY-169863

    RAR/RXR Inflammation/Immunology
    DC360 is a synthetic retinoid analogue of all-trans retinoic acid (ATRA) which induces RARβ expression. DC360 can be utilized in characterization of retinoid signalling pathways .
    DC360
  • HY-118761

    5,6-epoxy ATRA; 5,6-epoxy RA

    RAR/RXR Metabolic Disease
    all-trans-5,6-epoxy Retinoic acid (5,6-epoxy RA) is an agonist of all isoforms of the retinoic acid receptor (RAR; EC50s=77, 35, and 4 nM for RARα, RARβ, and RARγ, respectively). 5,6-epoxy RA (1 μM) also induces growth arrest of MCF-7 and NB4 cells in vitro. It is a natural metabolite of all-trans retinoic acid, which is a metabolite of vitamin A.
    5,6-Epoxyretinoic acid
  • HY-14649S3

    Vitamin A acid-d6; all-trans-Retinoic acid-d6; ATRA-d6

    Isotope-Labeled Compounds RAR/RXR PPAR Autophagy Endogenous Metabolite Cancer
    Retinoic acid-d6 is the deuterium labeled Retinoic acid[1]. Retinoic acid is a metabolite of vitamin A that plays important roles in cell growth, differentiation, and organogenesis. Retinoic acid is a natural agonist of RAR nuclear receptors, with IC50s of 14 nM for RARα/β/γ. Retinoic acid bind to PPARβ/δ with Kd of 17 nM. Retinoic acid acts as an inhibitor of transcription factor Nrf2 through activation of retinoic acid receptor alpha[2][3][4][5][6][7].
    Retinoic acid-d6
  • HY-111839

    CRABP-II ligand 1

    Ligands for Target Protein for PROTAC Cancer
    ATRA-hydroxyimino (CRABP-II ligand 1), the Retinoic acid (ATRA)-based moiety, binds to cIAP1 ligand (Bestatin) via a linker to form SNIPER to degrade CRABP-II in IMR-32 cells .
    ATRA-hydroxyimino
  • HY-12887R

    RP 73401 (Standard); RPR 73401 (Standard)

    Reference Standards Phosphodiesterase (PDE) Inflammation/Immunology Cancer
    Piclamilast (Standard) is the analytical standard of Piclamilast. This product is intended for research and analytical applications. Piclamilast (RP 73401) is a phosphodiesterase 4 (PDE4) inhibitor, with IC50 values of 16 nM and 2 nM in pig aorta and eosinophil soluble, respectively .
    Piclamilast (Standard)
  • HY-14649S5

    Vitamin A acid-d3; all-trans-Retinoic acid-d3; ATRA-d3

    Isotope-Labeled Compounds RAR/RXR PPAR Endogenous Metabolite Autophagy Cancer
    Retinoic acid-d3 is the deuterium labeled Retinoic acid (HY-14649). Retinoic acid is a metabolite of vitamin A that plays important roles in cell growth, differentiation, and organogenesis. Retinoic acid is a natural agonist of RAR nuclear receptors, with IC50s of 14 nM for RARα/β/γ. Retinoic acid bind to PPARβ/δ with Kd of 17 nM. Retinoic acid acts as an inhibitor of transcription factor Nrf2 through activation of retinoic acid receptor alpha .
    Retinoic acid-d3
  • HY-14649S6

    Vitamin A acid-d3-1; all-trans-Retinoic acid-d3-1; ATRA-d3-1

    Isotope-Labeled Compounds RAR/RXR PPAR Endogenous Metabolite Autophagy Metabolic Disease Cancer
    Retinoic acid-d3-1 is the deuterium labeled Retinoic acid (HY-14649). Retinoic acid is a metabolite of vitamin A that plays important roles in cell growth, differentiation, and organogenesis. Retinoic acid is a natural agonist of RAR nuclear receptors, with IC50s of 14 nM for RARα/β/γ. Retinoic acid bind to PPARβ/δ with Kd of 17 nM. Retinoic acid acts as an inhibitor of transcription factor Nrf2 through activation of retinoic acid receptor alpha .
    Retinoic acid-d3-1
  • HY-182728

    Cytochrome P450 Metabolic Disease
    CD564 (Compound 11b) is a cytochrome P450 CYP26A1 and CYP26B1 inhibitor, with IC50 values of 1.63 μM and 0.52 μM, respectively. Cytochrome P450 CYP26 enzymes clear all-trans retinoic acid (atRA) .
    CD564

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: